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Abstract
Methylenetetrahydrofolate reductase catalyzes the reduc-
tion of methylenetetrahydrofolate to methyltetrahydrofo-
late, which serves as the methyl donor for the conversion 
of homocysteine to methionine in the reaction catalyzed 
by methionine synthase. Recent studies have provided 
evidence for association of a common polymorphism of 
methylenetetrahydrofolate reductase with elevated lev-
els of blood homocysteine, a metabolite correlated with in-
creased cardiovascular risk in humans. In this chapter, we 
review earlier studies on the properties of the mammalian 
enzyme, interpreting these observations in the light of the 
deduced amino acid sequence for the human enzyme. The 
catalytic portion of the human enzyme shows significant 
sequence homologies with methylenetetrahydrofolate re-
ductase from bacterial sources, and in particular mutations 
that are known to cause elevated blood homocysteine lev-
els in humans affect residues that are conserved in the bac-
terial enzyme. Thus we believe that studies of mutant E. 
coli proteins will provide valuable information on the con-
sequences of human mutations of equivalent residues.
Properties of Mammalian Methylenetetrahydrofolate 
Reductase
The conversion of homocysteine to methionine re-
quires a sequence of three enzymatic reactions, which 
are catalyzed by serine hydroxymethyltransferase (4-
1), methylenetetrahydrofolate reductase (MTHFR [4-2]), 
and   cobalamin-dependent   methionine synthase (4-3), 
respectively. 
Serine + H4folate → Glycine + CH2 –H4folate      (1)
CH2 –H4folate + NADPH → CH3-H4folate + NADP+  (2)
CH3-H4folate + Homocysteine → H4folate + Methionine 
(3)
The combined action of these three enzymes results  in 
the methylation of homocysteine by transfer of a methyl 
group derived from the β-carbon of serine. Methionine 
can be converted to adenosylmethionine  (AdoMet) 
by adenosylmethionine synthetase, as shown in (4). 
AdoMet is an activated methyl donor, and serves to 
provide methyl groups in a wide variety of biological 
methylation reactions.
Methionine + ATP → AdoMet + tripolyphosphate  (4)
Methylenetetrahydrofolate reductase has been puri-
fied from a variety of bacterial and mammalian sources 
and has been shown to contain enzyme-bound FAD as 
a prosthetic group [1—6]. The flavin plays an essen-
tial role in the catalytic reaction. In the porcine enzyme, 
which has been purified to homogeneity [6] and exten-
sively studied, NADPH stoichiometrically 
reduces the flavin as indicated in (5).
FADPH + E ∙ FADox → NADP
+ + E ∙ FADred     (5)
This reaction is irreversible both in vivo and in vi-
tro [7], and imparts irreversibility to the entire reaction 
shown in (2). In the physiologic reaction, the reduced 
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enzyme—bound flavin is oxidized by methylenetetra-
hydrofolate (CH2-H4folate) in a reaction that is freely re-
versible [6], as shown in (6).
E ∙ FADred + CH2-H4folate ↔ E ∙ FADox + CH3-H4folate 
(6)
The reversibility of the reaction shown in (6) has been 
exploited in the standard assay for MTHFR [1,2,5], in 
which oxidation of [5-3H methyl]CH3-H4folate to CH2-
H4folate is coupled to the reduction of menadione to 
menadiol, and the resultant CH2-H4folate is subjected 
to acid decomposition in the presence of dimedone. 
In acid, CH2-H4folate decomposes to form [3H]-form-
aldehyde, and the formaldehyde-dimedone complex 
is extracted into toluene for quantitation of product 
formation.
Stereochemical and kinetic analyses of the reactions 
catalyzed by the porcine enzyme have shown that both 
NADPH and CH2-H4folate react at the si face of the en-
zyme-bound flavin [8], which is depicted in Figure 1. 
While X-ray structures have been determined for a vari-
ety of NADPH-dependent flavoprotein oxidoreductases 
[9—11], the majority of these proteins bind one or more 
of their substrates at the re face of the flavin [12]. Thus, 
the sequence motifs that have been identified in these 
proteins as being associated with flavin binding may 
not be the same for MTHFR.
Kutzbach and Stokstad [5] initially demonstrated 
that mammalian MTHFR activity is regulated by the 
AdoMet/adenosylhomocysteine ratio, with AdoMet in-
hibiting enzyme activity and inhibition being relieved 
by adenosylhomocysteine. Thus, the activity of MTHFR 
is adjusted in accord with the demand for methyl groups 
for biological methylation reactions. AdoMet binding to 
MTHFR results in a conformational change to a form of 
enzyme with decreased affinity for NADPH. NADPH 
and AdoMet play antagonistic roles in this regulation, 
with NADPH recruiting the active forms of the enzyme, 
and AdoMet recruiting inactive forms [13].
The native porcine MTHFR is a homodimer of 77 
kDa subunits, but when shadowed preparations of the 
individual dimers are viewed in the scanning trans-
mission electron microscope they show four clear lobes 
of density, rather than two [14]. These observations 
suggested that each subunit might contain two distinct 
regions. Limited proteolysis of the native enzyme with 
trypsin indeed results in cleavage of the 7 7 kDa sub-
unit into 40 and 37 kDa fragments, and cleavage is as-
sociated with the loss of inhibition by AdoMet, but the 
activity of the enzyme is unaffected [14]. Photoaffinity 
labeling of the enzyme with 8-azido-S-adenosylmethi-
onine results in specific labeling of the C-terminal 37 
kDa region [15].
The isolation of a cDNA coding for the human 
MTHFR and its recent sequencing [16,17] have pro-
vided considerable insight into the organization of the 
enzyme. The deduced amino acid sequence for this 
cDNA is shown in Figure 2, and corresponds to a mo-
lecular mass of 74,546 kDa. Underlined in Figure 2 are 
residues corresponding to peptides isolated from ho-
mogeneous porcine enzyme and sequenced by Ed-
man degradation. The N-terminal sequence of the por-
cine enzyme does not appear in the human cDNA, 
which may indicate that the cDNA isolated codes for a 
smaller isozyme of MTHFR or perhaps lacks sequence 
at the 5′-end.
In one experiment, the native porcine enzyme was 
first digested with trypsin and the N- and C-terminal 
fragments were separated by gel electrophoresis under 
denaturing conditions. The isolated fragments were 
cleaved with lysyl endoprotease (LysC), which cleaves 
the amide bond on the C-terminal side of lysyl resi-
dues. Peptides that were derived from the 40 kDa N-
terminal fragment correspond to residues 61-94, 219-
240, and 337-351 [16], while peptides that were derived 
from the 37 kDa C-terminal fragment correspond to 
residues 374-394, 420-445, 469-492, 531-543, and 598-
628 (JS Sumner and RG Matthews, unpublished data). 
These sequences define the cleavage point between the 
40 and 37 kDa fragments as lying between residues 351 
and 374. The sequence in this region with the greatest 
hydrophilicity and surface probability is K357RREED, 
and this is the probable site of cleavage of the native 
enzyme. The predicted mass of the C-terminal frag-
ment generated by cleavage between lysine357 and ar-
ginine358 is 34,863 Da, in moderately good agreement 
with the 37 kDa mass observed after cleavage of the 
porcine enzyme.
Figure 1. The structure of the isoalloxazine ring of flavin 
adenine dinucleotide as viewed from the si face, where 
both substrates of porcine liver methylenetetrahydrofolate 
reductase, NAD(P)H and CH2-H4folate, react.
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Properties of the Bacterial Methylenetetrahydrofolate 
Reductase Enzymes
Figure 2 also shows the alignment of the deduced 
amino acid sequence of human MTHFR with the se-
quences of the methylenetetrahydrofolate reductases 
from Escherichia coli and Salmonella typhimurium. These 
aligned sequences show 24% identity, so that the three-
dimensional structures of the bacterial enzymes and 
the N-terminal region of the human enzyme are al-
most certainly highly similar. The MTHFR from Esch-
erichia coli was initially characterized by Buchanan and 
his colleagues [3]. This enzyme was shown to be a fla-
voprotein, and was shown to catalyze the reduction of 
CH2-H4folate to CH3-H4folate. In contrast to the mam-
malian enzymes, the bacterial enzyme activity is not 
Figure 2. Alignment of the deduced amino-acid sequence of human methylenetetrahydrofolate reductase [16,17], des-
ignated mthfr, with the deduced amino acid sequences of the MetF proteins from E. coli [19] and S. typhimurium [20], 
designated ecometF and stymetF, respectively. Underlined residues indicate identities with residues in peptides iso-
lated from porcine liver methylenetetrahydrofolate reductase. Residues shown in bold are identical in all three de-
duced sequences. Bullets indicate the locations of three mutations that are associated with homocysteinemia in humans 
and that affect conserved residues in the aligned sequences. The numbering of the mthfr amino acid sequence assumes 
that the ATG codon in the cDNA beginning at nt 13 of the published sequence [16] is the initiator site for translation of 
the protein. 
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regulated by adenosylmethionine, in agreement with 
the lack of a C-terminal regulatory domain. This pro-
tein is encoded by the metF gene in both E. coli and S. 
typhimurium. The metF gene from both organisms has 
been sequenced [19,20]. We have succeeded in con-
structing an expression vector for overproduction of 
MTHFR from Escherichia coli plasmid pEJ3-1B, which 
contains the metF gene in a pBR322 plasmid [20]. In 
our vector, pCAS-5, the MTHFR coding sequence is 
placed under the control of the trc promoter, and ap-
proximately 20% of the total cellular protein is MTHFR 
when cells are grown in the presence of IPTG. We have 
recently purified the wild type bacterial enzyme to ho-
mogeneity, and have confirmed that the MTHFR pro-
tein is a flavoprotein. The homogenous enzyme ex-
hibits both CH3-H4folate-menadione oxidoreductase 
activity (7),
CH3-H4folate + menadione → CH2-H4folate + menadiol 
(7)
and NADH-menadione oxidoreductase activity (8). 
NADH + menadione → NAD+ + menadiol        (8)
Initial studies of partially purified MTHFR enzyme 
had indicated that NADH could supply reducing equiv-
alents for the reduction of CH2-H4folate, but further 
purification of the enzyme by Katzen and Buchanan 
resulted in the loss of NADH-CH2 -H4folate oxidoreduc-
tase activity [3]. However, in our enzyme preparations 
NADH-menadione oxidoreductase activity copurifies 
with CH3-H4folate-menadione oxidoreductase activity, 
and we presume that the physiologic reaction is given 
by (9).
NADH + CH2-H4folate → NAD+ + CH3-H4folate    (9)
Thus, the bacterial enzymes are able to bind FAD 
and catalyze the transfer of reducing equivalents from 
NADH to the enzyme-bound flavin and from reduced 
flavin to CH2-H4folate. Since these enzymes are only 
~33kDa (296 amino acids), the corresponding region 
of the human enzyme is likely to contain the residues 
necessary for FAD, NADPH, and CH2-H4folate bind-
ing. Thus the catalytic domain of the human enzyme is 
probably located in the N-terminal 40kDa region, while 
regulation by AdoMet is likely to require the C-termi-
nal domain. The sequence alignment indicates sev-
eral highly conserved regions of sequence, which are 
likely to contain residues critical to the binding of sub-
strates and FAD, and to catalysis of oxidoreduction of 
the substrates. 
Mutations Associated with Homocysteinemia in 
Humans and the Phenotypes of the Corresponding 
Bacterial Mutations
A number of mutations of human MTHFR that are 
associated with human disease have now been identi-
fied [16,17,21]. A subset of these mutations affect res-
idues that are identical in the sequences of the bac-
terial enzymes aligned in Figure 2. These mutations 
include Arg157Gln [16] and Thr227Met, as well as the 
polymorphism Ala222Val. In humans, the Thr227Met 
mutation in a homozygous state is associated with 
extremely low levels of activity (0–3%) and onset of 
symptoms within the first year after birth [21]. Thus 
far, the only patients with the Arg157Gln mutation are 
heterozygotes, with an uncharacterized second muta-
tion [16,21]. These patients have >6% residual activity 
and develop symptoms only during or after the second 
decade of life.
The Ala222Val polymorphism is thought to be as-
sociated with mild homocysteinemia in humans [17]. 
Homocysteinemia has been identified as an indepen-
dent risk factor for cardiovascular disease [22]. In-
deed, Kang and his colleagues [23] have described 
the association of a mild MTHFR deficiency, with in-
creased thermolability, with increased risk for cor-
onary artery disease. At the time this work was pub-
lished, the sequence of MTHFR was not known, and so 
the mutation(s) responsible for this phenotype could 
not be not identified. Because the catalytic mechanism 
and tertiary structure of the N-terminal region of the 
human enzyme is likely to be very similar to those of 
the bacterial enzymes, we have undertaken the con-
struction and expression of mutations that correspond 
to Arg157Gln, Thr227Met, and Ala222 Val in the E. coli 
enzyme. Characterization of these mutant enzymes is 
now in progress.
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